On 24 December 2020, the European Union and the United Kingdom reached an agreement in principle on the EU-UK Trade and Cooperation Agreement (the Agreement). This was the result of many months of detailed negotiation within an increasingly difficult political environment. The final Agreement does not cover all of the aspects about which life sciences companies have been concerned, and there are areas that will likely be the subject of further discussion during the implementation of the Agreement. However, many view the Agreement as being an important first step in the UK’s continuing relationship with the EU. We set out below a summary of the key aspects of the Agreement relevant to life sciences companies.
Latest Post
More Posts
EU Clinical Trials Regulation: The Clinical Trials Information System expected to go live by December 2021, according to the EMA
EMA Guidance on fast-tracking the development and approval of treatments and vaccines for COVID-19
Guidance from the EU EMA and UK MHRA on clinical trials during the COVID-19 Pandemic
EMA Guidance on Comparability Exercise for ATMPs
Latest Developments in the Transparency Activities of the European Medicines Agency
Latest Updates on Good Clinical Practice for Advanced Therapies in the EU
Impact of UK’s Temporary Tariff Regime on Life Sciences
European Court ruling on SPCs for medical devices
Update on the EMA’s Policy on Publication of Clinical Data
Subscribe: Subscribe via RSS
Blogs
Firm/Org